Hypersensitivity to inhaled TOBI ® following reaction to gentamicin
dc.contributor.author | Spigarelli, Michael G. | en_US |
dc.contributor.author | Hurwitz, Martin E. | en_US |
dc.contributor.author | Nasr, Samya Z. | en_US |
dc.date.accessioned | 2006-04-19T14:23:27Z | |
dc.date.available | 2006-04-19T14:23:27Z | |
dc.date.issued | 2002-04 | en_US |
dc.identifier.citation | Spigarelli, Michael G.; Hurwitz, Martin E.; Nasr, Samya Z. (2002)."Hypersensitivity to inhaled TOBI ® following reaction to gentamicin." Pediatric Pulmonology 33(4): 311-314. <http://hdl.handle.net/2027.42/35320> | en_US |
dc.identifier.issn | 8755-6863 | en_US |
dc.identifier.issn | 1099-0496 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/35320 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11921461&dopt=citation | en_US |
dc.description.abstract | Cystic fibrosis (CF) is the most common autosomal-recessive disease in Caucasians. Colonization with Pseudomonas aeruginosa ( P. aeruginosa ) of the CF airways causes deterioration of pulmonary status. TOBI ® (Tobramycin solution for inhalation) is an inhaled antibiotic that can improve the pulmonary disease. We report on a 9-year old boy with CF who developed a rash following a course of IV gentamicin. The rash resolved after its discontinuation. However, the rash returned all over his body, with the start of inhalation of TOBI ® therapy. We desensitized the patient using escalating doses of inhaled TOBI ® . He tolerated the procedure well, and continues to be on TOBI ® 9 months after desensitization on a once-a-day regimen. Pediatr Pulmonol. 2002; 33:311-314. © 2002 Wiley-Liss, Inc. | en_US |
dc.format.extent | 113823 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Miscellaneous Medical | en_US |
dc.title | Hypersensitivity to inhaled TOBI ® following reaction to gentamicin | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Pediatric Pulmonary Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center. Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Pediatric Pulmonary Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center. Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Pediatric Pulmonary Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center. Ann Arbor, Michigan ; Department of Pediatrics, University of Michigan Medical Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0212. | en_US |
dc.identifier.pmid | 11921461 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/35320/1/10049_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/ppul.10049 | en_US |
dc.identifier.source | Pediatric Pulmonology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.